SCHEMBL4329892

SCHEMBL4329892

CN1CCN(c2cc(N3CCN(c4ccc(Cl)c(Cl)c4)CC3)c(F)cc2C=NNC(N)=S)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.52
ALDH1A1 P00352 8/20 0.52
LMNA P02545 5/20 0.52
HTT P42858 4/20 0.52
ALOX12 P18054 4/20 0.52
HPGD P15428 2/20 0.52
MAPK1 P28482 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
SMN1; SMN2 Q16637 6/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
GAA P10253 2/20 0.41
TDP1 Q9NUW8 1/20 0.40
MAOB P27338 1/20 0.40
POLB P06746 1/20 0.39
MCL1 Q07820 1/20 0.39
CSF1R P07333 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
KDM4E B2RXH2 2/20 0.38
PHGDH O43175 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4329890 1.00 MAPT (0.52) MAPTALDH1A1LMNAHTTALOX12
SCHEMBL4451251 0.90 ALDH1A1 (0.50) MAPTALDH1A1LMNAHTTALOX12
SCHEMBL4451250 0.90 ALDH1A1 (0.50) MAPTALDH1A1LMNAHTTALOX12
SCHEMBL4336300 0.88 ALDH1A1 (0.52) MAPTALDH1A1LMNAHTTALOX12
SCHEMBL4336306 0.88 ALDH1A1 (0.52) MAPTALDH1A1LMNAHTTALOX12
SCHEMBL4327771 0.87 MAPT (0.41) MAPTALDH1A1LMNAHTTALOX12
SCHEMBL4327767 0.87 MAPT (0.41) MAPTALDH1A1LMNAHTTALOX12
SCHEMBL4337050 0.87 ALDH1A1 (0.41) MAPTALDH1A1LMNAHTTALOX12
SCHEMBL4337053 0.87 ALDH1A1 (0.41) MAPTALDH1A1LMNAHTTALOX12
SCHEMBL4324349 0.87 MAPT (0.50) MAPTALDH1A1LMNAHTTALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3619/4885ALDH1A1 1459/4885LMNA 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.